Connor, Clark & Lunn Investment Management Ltd. Deciphera Pharmaceuticals, Inc. Transaction History

Connor, Clark & Lunn Investment Management Ltd.

$18.8 Billion
Q3 2024

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 09, 2024	BUY	$13.58 - $17.36 $378,909 - $484,378	27,902 Added 11.11%	279,047 $4.39 Million
Q4 2023 Feb 09, 2024	BUY	$10.11 - $16.54 $1.81 Million - $2.96 Million	178,973 Added 247.98%	251,145 $4.05 Million
Q3 2023 Nov 13, 2023	BUY	$12.46 - $15.48 $78,448 - $97,462	6,296 Added 9.56%	72,172 $918,000
Q2 2023 Aug 10, 2023	BUY	$13.28 - $15.96 $663,853 - $797,824	49,989 Added 314.65%	65,876 $927,000
Q1 2023 May 09, 2023	BUY	$14.26 - $22.1 $226,548 - $351,102	15,887 New	15,887 $245,000
Q2 2022 Aug 05, 2022	SELL	$9.11 - $13.98 $818,852 - $1.26 Million	-89,885 Closed	0 $0
Q1 2022 May 12, 2022	BUY	$6.87 - $11.11 $362,440 - $586,130	52,757 Added 142.09%	89,885 $833,000
Q4 2021 Feb 10, 2022	BUY	$7.7 - $37.13 $285,885 - $1.38 Million	37,128 New	37,128 $363,000

Others Institutions Holding DCPH

# of Institutions

Shares Held

293K

Call Options Held

500

Put Options Held

View Full List

About Deciphera Pharmaceuticals, Inc.

Ticker DCPH
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 66,822,100
Description
Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gas...

More about DCPH

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Connor, Clark & Lunn Investment Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Connor, Clark & Lunn Investment Management Ltd. with notifications on news.

Account